Johnson & Johnson (JNJ)
| Market Cap | 427.26B |
| Revenue (ttm) | 96.04B |
| Net Income (ttm) | 19.16B |
| Shares Out | 2.61B |
| EPS (ttm) | 7.18 |
| PE Ratio | 22.76 |
| Forward PE | 16.89 |
| Dividend | $4.45 (2.72%) |
| Ex-Dividend Date | Nov 21, 2022 |
| Volume | 11,501,250 |
| Open | 161.70 |
| Previous Close | 162.00 |
| Day's Range | 161.05 - 163.43 |
| 52-Week Range | 155.72 - 186.69 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 188.75 (+15.5%) |
| Earnings Date | Jan 24, 2023 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; N... [Read more]
Financial Performance
In 2022, JNJ's revenue was $93.78 billion, an increase of 13.55% compared to the previous year's $82.58 billion. Earnings were $20.88 billion, an increase of 41.89%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $188.75, which is an increase of 15.50% from the latest price.
News
The 7 Best Climate Change Stocks to Buy for 2023
The concept of best climate change stocks to buy for 2023 presents a critically ethical tone. According to multiple scientists and investigative reports, human-caused environmental impact imposed many...
J&J Faces Longer Path to Resolving Talc Lawsuits
The company's court loss over baby-powder litigation could force it to defend thousands of lawsuits case by case, just as it navigates the biggest restructuring in its 137-year history.
J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits
A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.
5 Dividend King Stocks Gurus Are Feasting On
According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson ...
Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
Nachawati Law Group: Ovarian cancer victims deserve day in court PHILADELPHIA , Jan. 30, 2023 /PRNewswire/ -- Trial lawyers with the Nachawati Law Group praised a ruling by the U.S. Court of Appeals f...
Court tosses bankruptcy petition by Johnson & Johnson's talc unit
An appeals court on Monday dismissed the Chapter 11 bankruptcy petition of J&J's talc subsidiary, which the company formed to resolve thousands of lawsuits.
Johnson And Johnson Stock Slips After Missing The Mark For Earnings
Johnson and Johnson's stock took a tumble before its Q4 2022 earnings call, and the numbers reported didn't help it bounce back. Here's what happened.
Johnson & Johnson stock drops following dismissal of bankruptcy strategy tied to talc lawsuits
#Johnson&Johnson #J&J Yahoo Finance anchors Allie Canal, Seana Smith, and Dave Briggs report on Johnson & Johnson stock down slightly on Monday afternoon over concern of the fallout from the talcum po...
Johnson and Johnson loses $17 billion in market value after appeals court denies company bankruptcy escape in baby powder lawsuits
Johnson & Johnson continues to stand by the safety of its baby powder formula and has denied that it contains cancer-causing asbestos.
Why Is Johnson & Johnson (JNJ) Stock Down Today?
It's a sea of red in the stock market today, but some companies are clearly under-performing others. One such notable decliner today is Johnson & Johnson (NYSE: JNJ), with shares of JNJ stock droppin...
Appeals court dismisses Johnson and Johnson talc bankruptcy case
CNBC's Meg Tirrell joins 'Halftime Report' to report on the U.S. appeals court decision to toss out Johnson and Johnson's talc powder settlements in to a bankruptcy case, the reasons behind the ruling...
J&J's Talc Bankruptcy Case Thrown Out by Appeals Court
A federal appeals court said Johnson & Johnson's LTL Management can't use bankruptcy to resolve numerous talc-injury lawsuits.
Johnson & Johnson's talc bankruptcy case rejected by appeals court
Johnson & Johnson's strategy to use bankruptcy to resolve the multibillion-dollar litigation over claims its talc products cause cancer was rejected by a federal appeals court on Monday, but the healt...
Johnson & Johnson stock takes a dive after WSJ report that federal appeals court rejected talc bankruptcy case
Shares of Johnson & Johnson JNJ, -2.56% took a dive in midday trading Monday, after The Wall Street Journal reported that a federal appeals court rejected the consumer products and drug maker's move t...
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projec...
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
J&J Gets Ready to Break up With Tylenol
Johnson & Johnson's consumer business was the only division to deliver growth in the fourth quarter.
‘Tripledemic' demand for Motrin and Tylenol fueled year-end sales in J&J's consumer business
As cases of COVID, flu and respiratory syncytial virus surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson's JNJ c...
Johnson & Johnson fourth-quarter earnings down 25%
The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.
J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat
J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.
Q4 Earnings Season Heats Up: JNJ, MMM, GE & More
Whether pre-market futures are reacting to results or just doing some profit-taking off recent highs is hard to tell -- the Dow is -150 points at this hour, the S&P 500 is -20 and the Nasdaq -85 point...
J&J CFO on Earnings Forecast, Costs and Consumer Spinoff
Johnson & Johnson CFO Joseph Wolk discusses the company's stronger-than-expected earnings forecast for 2023 and cost pressures with Guy Johnson and Alix Steel on "Bloomberg Markets." Follow Bloomberg ...
Johnson & Johnson reports mixed earnings, strong consumer demand
#Johnson&Johnson Yahoo Finance's Anjalee Khemlani joins the Live show to discuss fourth-quarter earnings for Johnson & Johnson.